Amina I Malik1, Jill S Huppert. 1. University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA.
Abstract
STUDY OBJECTIVE: To describe (1) the treatment interval for adolescent females with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), or Trichomonas vaginalis (TV); (2) the proportion treated in < or =7 days; and (3) factors influencing the treatment interval. DESIGN AND PARTICIPANTS: Charts of sexually active females from an urban teen health center who participated in a larger study and were positive for CT, GC or TV (N = 58) were retrospectively reviewed for dates of treatment, and compared to demographic and symptom data. The treatment interval was defined as days from visit to treatment. CT and/or GC were analyzed together (CT/GC) because presumptive treatment covered both infections, and the diagnostic test (nucleic acid amplification) differed from that of TV (wet mount or culture). RESULTS: The median treatment interval was 0 days for TV, 5 days for CT/GC, and 3 days for any STI. Overall, 39 (69%) were treated within 7 days of their visit. Those with TV were more likely than those with CT/GC to receive treatment at their initial visit (58% vs. 6%). Genitourinary symptoms increased the odds of treatment in < or =7 days. The treatment interval was significantly shorter for subjects who had their prescriptions phoned to a pharmacy than for those who returned to clinic for treatment (median 2.5 vs. 8 days). CONCLUSIONS: Where presumptive treatment was uncommon, providers were more likely to prescribe same-day therapy to symptomatic patients or those with TV on wet mount. Additional strategies are needed to improve the proportion of adolescent females treated in < or =7 days.
STUDY OBJECTIVE: To describe (1) the treatment interval for adolescent females with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), or Trichomonas vaginalis (TV); (2) the proportion treated in < or =7 days; and (3) factors influencing the treatment interval. DESIGN AND PARTICIPANTS: Charts of sexually active females from an urban teen health center who participated in a larger study and were positive for CT, GC or TV (N = 58) were retrospectively reviewed for dates of treatment, and compared to demographic and symptom data. The treatment interval was defined as days from visit to treatment. CT and/or GC were analyzed together (CT/GC) because presumptive treatment covered both infections, and the diagnostic test (nucleic acid amplification) differed from that of TV (wet mount or culture). RESULTS: The median treatment interval was 0 days for TV, 5 days for CT/GC, and 3 days for any STI. Overall, 39 (69%) were treated within 7 days of their visit. Those with TV were more likely than those with CT/GC to receive treatment at their initial visit (58% vs. 6%). Genitourinary symptoms increased the odds of treatment in < or =7 days. The treatment interval was significantly shorter for subjects who had their prescriptions phoned to a pharmacy than for those who returned to clinic for treatment (median 2.5 vs. 8 days). CONCLUSIONS: Where presumptive treatment was uncommon, providers were more likely to prescribe same-day therapy to symptomatic patients or those with TV on wet mount. Additional strategies are needed to improve the proportion of adolescent females treated in < or =7 days.
Authors: Robert E Johnson; Wilbert J Newhall; John R Papp; Joan S Knapp; Carolyn M Black; Thomas L Gift; Richard Steece; Lauri E Markowitz; Owen J Devine; Cathleen M Walsh; Susan Wang; Dorothy C Gunter; Kathleen L Irwin; Susan DeLisle; Stuart M Berman Journal: MMWR Recomm Rep Date: 2002-10-18
Authors: Janet S St Lawrence; Daniel E Montaño; Danuta Kasprzyk; William R Phillips; Keira Armstrong; Jami S Leichliter Journal: Am J Public Health Date: 2002-11 Impact factor: 9.308
Authors: Sami L Gottlieb; John M Douglas; Mark Foster; D Scott Schmid; Daniel R Newman; Anna E Baron; Gail Bolan; Michael Iatesta; C Kevin Malotte; Jonathan Zenilman; Martin Fishbein; Thomas A Peterman; Mary L Kamb Journal: J Infect Dis Date: 2004-08-05 Impact factor: 5.226
Authors: Marcia L Shew; J Dennis Fortenberry; Wanzhu Tu; Beth E Juliar; Byron E Batteiger; Brahim Qadadri; Darron R Brown Journal: Arch Pediatr Adolesc Med Date: 2006-02
Authors: Jennifer L Reed; Lauren Simendinger; Sarah Griffeth; Hye Grace Kim; Jill S Huppert Journal: J Adolesc Health Date: 2009-10-12 Impact factor: 5.012
Authors: Jill S Huppert; Jennifer L Reed; Jennifer Knopf Munafo; Rachel Ekstrand; Gordon Gillespie; Carolyn Holland; Maria T Britto Journal: Pediatrics Date: 2012-07-02 Impact factor: 7.124
Authors: Laura McWhirter; Yingbo Lou; Sarah Reingold; Sarah Warsh; Tara Thomas-Gale; Christine Haynes; Deborah Rinehart; Karen A Wendel; Holly M Frost Journal: Sex Transm Dis Date: 2022-01-10 Impact factor: 3.868